Chemogenomics: bridging a drug discovery gap.
With the successful completion of the human genome sequencing and the resulting plethora of genetic information now available novel technologies and applications have to be established to translate the huge amount of data generated into successful biological and biomedical research programs. The integration of various drug discovery disciplines within the parallel quest for novel targets and new molecular entities has meanwhile given rise to a quite popular term in pharmaceutical research named "chemogenomics". This review article gives an overview of the disciplines involved in this field and discusses the possible implications of this novel paradigm in drug discovery for the near future.
Bleicher
Konrad H
KH
F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Discovery Chemistry, Basel, CH-4070, Switzerland. konrad.bleicher@roche.com
D000465:Algorithms; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods; D023281:Genomics / Q000379:methods*; D008024:Ligands; D008958:Models, Molecular; D014584:User-Computer Interface
D008024:Ligands